Danaher Corporation — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; comparisons are to the periods ended July 1, 2022. Danaher reports Biotechnology, Life Sciences, Diagnostics, and Environmental & Applied Solutions (EAS). Amounts are in U.S. dollars.
Financial performance
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Sales | $7.157B | $7.751B | $14.324B | $15.439B |
| Core sales change (non-GAAP) | (7.0)% | — | (5.5)% | — |
| Gross margin | 56.5% | 60.9% | 58.7% | 61.1% |
| Operating profit | $1.429B | $2.205B | $3.223B | $4.377B |
| Operating margin | 20.0% | 28.4% | 22.5% | 28.4% |
| Net earnings | $1.106B | $1.680B | $2.556B | $3.405B |
| Diluted EPS | $1.49 | $2.25 | $3.42 | $4.56 |
| Operating cash flow | — | — | $3.873B | $3.968B |
Q2 sales fell 7.5% reported; currency translation reduced sales 0.5 percentage points. First-half sales fell 7.0% reported, including a 1.5-point currency headwind. Price increases partly offset volume and mix pressures. Lower COVID-19-related demand was the main source of core-sales declines.
Segment sales, Q2 (year-over-year): Biotechnology $1.885B, down 17.0%; Life Sciences $1.796B, up 5.5%; Diagnostics $2.231B, down 13.0%; EAS $1.245B, up 2.0%. Biotechnology and Diagnostics operating margins fell sharply, while EAS first-half margin improved.
Cash, debt and liquidity
- Cash and equivalents were $8.575B at June 30, 2023, versus $5.995B at year-end 2022. First-half cash flow from operations was $3.873B; investing activities used $735M and financing activities used $470M.
- Total debt was $19.875B, including $1.590B current and $18.285B long-term, versus $19.677B at year-end. The company remained in compliance with debt covenants. It had a $5.0B revolving credit facility expiring August 2024.
- Capital expenditures were $616M in the first half; management forecast approximately $1.5B for full-year 2023. Cash dividends paid were $422M in the first half. No shares were repurchased in Q2.
Material changes and management commentary
- Biotechnology demand weakened amid declining COVID-19 vaccine and therapeutics activity, customer inventory reductions, and tighter financing for emerging biotech companies. Danaher expected these pressures to continue at least through the second half of 2023.
- Diagnostics’ decline chiefly reflected lower COVID-19 testing demand; non-respiratory molecular diagnostic testing sales grew more than 30% in Q2. Life Sciences benefited from research, academic and applied-market demand, while EAS growth was led by water-quality businesses.
- Operating margin pressure reflected lower sales and unfavorable mix, inventory write-offs, higher sales and marketing and labor costs, and restructuring/productivity initiatives. Q2 cost of sales included $87M of charges, primarily excess Biotechnology inventory. The company also recorded $34M of impairments related to technology, other assets and customer relationships, plus a $14M facility impairment.
- Interest expense rose to $67M in Q2 and $135M in the first half, mainly due to higher rates on euro commercial paper. Higher cash balances and rates lifted interest income to $59M and $107M, respectively.
Outlook, risks and contingencies
- Danaher targeted completion of the EAS separation as Veralto in Q4 2023, subject to board approval, financing, tax opinions and rulings, and other regulatory approvals. Separation costs were $37M in Q2 and $65M in the first half. EAS remained in continuing operations at period-end.
- Management expected an effective tax rate of approximately 19.5% for the remainder of 2023 and forecast full-year capital spending of approximately $1.5B. At June 30 exchange rates, currency was expected to increase second-half sales by about 1.0%, leaving full-year sales essentially flat versus 2022; this is an exchange-rate sensitivity, not a sales-growth forecast.
- Key risks include continuing post-pandemic demand normalization, biotechnology funding and China project delays/cancellations, competition and market cyclicality, foreign-exchange exposure, supply and labor costs, regulatory and product risks, and execution and tax treatment of the planned separation.
- The IRS settled proposed adjustments concerning self-insurance premium income for 2016–2018; the settlement had no material financial-statement or cash-flow impact, but the audit remains open on other matters and similar adjustments could be proposed for later years. The filing also reports a $46M impairment of equity-method investments.
- Management reported effective disclosure controls and no material changes to critical accounting estimates. Biotechnology process and systems integration was being implemented in phases during 2023.
Investor verification priorities
- Track whether Biotechnology and Diagnostics demand stabilizes, especially COVID-related products, biotech funding conditions, and China orders.
- Assess whether margins recover as excess inventory charges, cost actions and lower sales volumes evolve.
- Confirm the timing, approvals, financing and tax conditions for the Veralto separation and monitor related costs.
- Reconcile cash generation, debt maturities and commercial-paper funding needs against the company’s capital-spending and dividend plans.
- Monitor the remaining IRS audit matters and any potential tax exposure from later periods.